Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care.
Inferred from the date. No official record confirms this meeting took place.
Video
Other votes this committee recorded that day(11)
These votes are recorded against this committee on the same date. The official sources do not say which meeting each was taken at, so they are listed separately rather than attributed to this one.
S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.
S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute
Committee ordered favorably reported the following business items: S. 2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, with an amendment in the nature of a substitute; S. 4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, with an amendment in the nature of a substitute; S. 4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, with an amendment in the nature of a substitute; S. 5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, with an amendment in the nature of a substitute; S. 1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, with an amendment in the nature of a substitute; S. 3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, with an amendment in the nature of a substitute; S. 3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, with an amendment in the nature of a substitute; S. 494, to establish a national plan to coordinate research on epilepsy, with an amendment in the nature of a substitute; S. 4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, with an amendment in the nature of a substitute; S. 1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, with an amendment in the nature of a substitute; and S. 380, to improve obstetric emergency care, with an amendment in the nature of a substitute.